Riverain Technologies, an industry leader and innovator in proprietary
image analysis and machine learning technologies, announced today that
the United States Patent and Trademark Office (USPTO) has awarded the
company a broad patent for its technology that forms a vessel
suppressed, chest CT series using deep learning and synthetic data
modeling. The patent holds enormous promise for improving the detection
and diagnosis of lung cancer at an earlier stage while making clinicians
more efficient, a first for computer aided detection.
Riverain has been issued U.S. Patent 9,990,743 for its
methodology to selectively remove anatomical structures from CT scans to
optimize reading accuracy and efficiency for lung cancer detection. The
technology is used in the company’s premier software, ClearRead CT™. ClearRead
CT is proven to lead to more accurate and efficient detection of
lung nodules, the early indicator of lung cancer. A range of possible
applications exists within other imaging modalities including MRI,
positron emission tomography (PET), full field digital mammography and
tomosynthesis, where normal structures interfere with the detection and
diagnosis of disease.
Riverain Technologies is a clinical AI software innovator that develops
solutions to aid clinicians in the early detection of disease. For more
information visit: http://www.riveraintech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180613005731/en/
Riverain TechnologiesKelley Wright, firstname.lastname@example.org